Detalhe da pesquisa
1.
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
Medicina (Kaunas)
; 60(2)2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38399583
2.
Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
Eur J Gastroenterol Hepatol
; 36(6): 728-734, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38625825
3.
Gut community alterations associated with Clostridioides difficile colonization in hospitalized gastroenterological patients with or without inflammatory bowel disease.
Front Microbiol
; 13: 988426, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36147861
4.
Distinct Types of Gut Microbiota Dysbiosis in Hospitalized Gastroenterological Patients Are Disease Non-related and Characterized With the Predominance of Either Enterobacteriaceae or Enterococcus.
Front Microbiol
; 11: 120, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32117143